A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol

被引:201
|
作者
Hohmann, FP [1 ]
Macklon, NS [1 ]
Fauser, BCJM [1 ]
机构
[1] Erasmus MC, Div Reprod Med, Dept Obstet & Gynecol, NL-3015 GD Rotterdam, Netherlands
来源
关键词
D O I
10.1210/jc.2002-020788
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Extending the FSH window for multifollicular development by administering FSH from the midfollicular phase onward constitutes a novel mild protocol for ovarian stimulation for in vitro fertilization (IVF) based on the physiology of single dominant follicle selection in normo-ovulatory women. We compared outcomes from this protocol with two other stimulation protocols. One hundred and forty-two normo-ovulatory patients with an indication for IVF (or IVF/ICSI) were randomized to a GnRH agonist long protocol (group A; n = 45) or one of two GnRH antagonist protocols commencing recombinant FSH on cycle d 2 (group B; n = 48) or cycle d 5 (group C; n = 49). A fixed dose (150 IU/d) of rFSH was used for ovarian stimulation, and GnRH antagonist cotreatment was initiated on the day when the leading follicle reached 14 mm diameter. Group C showed a shorter duration of stimulation (median duration, 11, 9, and 8 d for groups A, B, and C, respectively; P < 0.001), reflected in a significantly lower total dose of rFSH used (median amount of rFSH, 1650, 1350, and 1200 IU for groups A, B, and C, respectively; P < 0.001). In group C more cycles were cancelled during the stimulation phase due to insufficient response, resulting in a lower percentage of oocyte retrievals (84%, 73%, and 63% for groups A, B, and C; P = 0.02). However, women in group C obtained better quality embryos (percentage of embryo score of 1 for best embryo, 29%, 37%, and 61% for groups A, B, and C, respectively; P = 0.008), resulting in more transfers per oocyte retrieval (68%, 71%, and 90% for groups A, B, and C, respectively; P = 0.04). After profound ovarian stimulation (groups A and B) only 7% of the patients who retrieved four oocytes or less conceived, whereas after mild stimulation (group C) 67% of these patients conceived (P < 0.01). Overall, no differences were found among the three groups comparing pregnancy rate per started IVF cycle. In conclusion, application of the described mild ovarian stimulation protocol resulted in pregnancy rates per started IVF cycle similar to those observed after profound stimulation with GnRH agonist cotreatment despite shorter stimulation and a 27% reduction in exogenous FSH. A higher cancellation rate before oocyte retrieval was compensated by improved embryo quality concomitant with a higher chance of undergoing embryo transfer. A relatively low number of oocytes retrieved after mild ovarian stimulation distinctly differs from the pathological reduction in the number of oocytes retrieved after profound ovarian stimulation (poor response) associated with poor IVF outcome. The relatively small number of oocytes obtained after mild ovarian stimulation may represent the best of the cohort in a given cycle.
引用
收藏
页码:166 / 173
页数:8
相关论文
共 50 条
  • [1] A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol -: Response
    Fauser, BCJM
    Macklon, NS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09): : 4510 - 4511
  • [2] Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment
    Beckers, NGM
    Macklon, NS
    Eijkemans, MJ
    Ludwig, M
    Felberbaum, RE
    Diedrich, K
    Bustion, S
    Loumaye, E
    Fauser, BCJM
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09): : 4186 - 4192
  • [3] In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols
    Farhi, Jacob
    Ben-Haroush, Avi
    Lande, Yehezkel
    Sapir, Onit
    Pinkas, Haim
    Fisch, Benjamin
    [J]. FERTILITY AND STERILITY, 2009, 91 (02) : 377 - 382
  • [4] A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization
    Berin, Inna
    Stein, Daniel E.
    Keltz, Martin D.
    [J]. FERTILITY AND STERILITY, 2010, 93 (02) : 360 - 363
  • [5] A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women with oral contraceptives before in vitro fertilization
    Barmat, LI
    Chantilis, SJ
    Hurst, BS
    Dickey, RP
    [J]. FERTILITY AND STERILITY, 2005, 83 (02) : 321 - 330
  • [6] Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant follicle-stimulating hormone on follicular fluid levels of adhesion molecules during in vitro fertilization
    Fornaro, Felice
    Cobellis, Luigi
    Mele, Daniela
    Tassou, Argyro
    Badolati, Barbara
    Sorrentino, Simona
    De Lucia, Domenico
    Colacurci, Nicola
    [J]. FERTILITY AND STERILITY, 2007, 87 (01) : 39 - 47
  • [7] Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH
    Ubaldi, F
    Camus, M
    Smitz, J
    Bennink, HC
    VanSteirteghem, A
    Devroey, P
    [J]. FERTILITY AND STERILITY, 1996, 66 (02) : 275 - 280
  • [8] Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH
    Ubaldi, F
    Camus, M
    Smitz, J
    Bennink, HJTC
    Van Steirteghem, A
    Devroey, P
    [J]. FERTILITY AND STERILITY, 1998, 69 (02) : 28S - 33S
  • [9] Minimal stimulation using gonadotropin-releasing hormone (GnRH) antagonist and recombinant human follicle-stimulating hormone versus GnRH antagonist multiple-dose protocol in low responders undergoing in vitro fertilization/intracytoplasmic sperm injection
    Kim, Chung-Hoon
    Kim, So-Ra
    Cheon, Yong-Pil
    Kim, Sung-Hoon
    Chae, Hee-Dong
    Kang, Byung-Moon
    [J]. FERTILITY AND STERILITY, 2009, 92 (06) : 2082 - 2084
  • [10] The use of Recombinant Luteinizing Hormone in Addition to Recombinant Follicle-stimulating Hormone in Ovarian Stimulation with the GnRH-antagonist Protocol
    Baruffi, Ricardo L. R.
    Mauri, Ana L.
    Petersen, Claudia G.
    Felipe, Valeria
    Martins, Anice M. C.
    Cornicelli, Joao
    Cavagna, Mario
    Oliveira, Joao B. A.
    Franco, Jose G., Jr.
    [J]. JORNAL BRASILEIRO DE REPRODUCAO ASSISTIDA, 2006, 10 (04): : 9 - 16